United Therapeutics Corporation
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$18Mgeneral payments (2019-2025)
$1.3Mresearch payments (2019-2025)
14,382clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Lana Melendres Groves | Albuquerque, NM | Pulmonary Disease | $559,128.43 |
| George Semeniuk | Newport Beach, CA | Hematology & Oncology | $478,500.00 |
| Jorge Mallea | Jacksonville, FL | Pulmonary Disease | $453,257.15 |
| Paul Forfia | Philadelphia, PA | Cardiovascular Disease | $419,841.06 |
| Steven Nathan | Falls Church, VA | Pulmonary Disease | $401,981.83 |
| Franck Rahaghi | Weston, FL | Pulmonary Disease | $383,164.02 |
| Jason Stienecker | Lima, OH | Pulmonary Disease | $344,698.79 |
| Hunter Champion | Columbus, GA | Cardiovascular Disease | $331,939.14 |
| John Ryan | Salt Lake City, UT | Cardiovascular Disease | $305,949.48 |
| Ricardo Restrepo-Jaramillo | Tampa, FL | Pulmonary Disease | $301,429.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.